Cancer and Metastasis Reviews最新文献

The roles of PD-L1 in the various stages of tumor metastasis. PD-L1 在肿瘤转移各阶段中的作用。

IF 7.7 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-05-11 DOI: 10.1007/s10555-024-10189-4

Yinjun He, Ming Zhu, Xuan Lai, Honghe Zhang, Weiqin Jiang

{"title":"The roles of PD-L1 in the various stages of tumor metastasis.","authors":"Yinjun He, Ming Zhu, Xuan Lai, Honghe Zhang, Weiqin Jiang","doi":"10.1007/s10555-024-10189-4","DOIUrl":"10.1007/s10555-024-10189-4","url":null,"abstract":"The interaction between tumor programmed death ligand 1 (PD-L1) and T-cell programmed cell death 1 (PD-1) has long been acknowledged as a mechanism for evading immune surveillance. Recent studies, however, have unveiled a more nuanced role of tumor-intrinsic PD-L1 in reprograming tumoral phenotypes. Preclinical models emphasize the synchronized effects of both intracellular and extracellular PD-L1 in promoting metastasis, with intricate interactions with the immune system. This review aims to summarize recent findings to elucidate the spatiotemporal heterogeneity of PD-L1 expression and the pro-metastatic roles of PD-L1 in the entire process of tumor metastasis. For example, PD-L1 regulates the epithelial-to-mesenchymal transition (EMT) process, facilitates the survival of circulating tumor cells, and induces the formation of immunosuppressive environments at pre-metastatic niches and metastatic sites. And the complexed and dynamic regulation process of PD-L1 for tumor metastasis is related to the spatiotemporal heterogeneity of PD-L1 expression and functions from tumor primary sites to various metastatic sites. This review extends the current understandings for the roles of PD-L1 in mediating tumor metastasis and provides new insights into therapeutic decisions in clinical practice.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1475-1488"},"PeriodicalIF":7.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140907965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Healthcare disparities, screening, and molecular testing in the changing landscape of non-small cell lung cancer in the United States: a review. 美国非小细胞肺癌变化中的医疗差距、筛查和分子检测：综述。

IF 4.4 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-05-16 DOI: 10.1007/s10555-024-10187-6

Razelle Kurzrock, Aadel A Chaudhuri, David Feller-Kopman, Narjust Florez, Jed Gorden, Ignacio I Wistuba

{"title":"Healthcare disparities, screening, and molecular testing in the changing landscape of non-small cell lung cancer in the United States: a review.","authors":"Razelle Kurzrock, Aadel A Chaudhuri, David Feller-Kopman, Narjust Florez, Jed Gorden, Ignacio I Wistuba","doi":"10.1007/s10555-024-10187-6","DOIUrl":"10.1007/s10555-024-10187-6","url":null,"abstract":"Inequitable access to care continues to hinder improvements in diagnosis and treatment of lung cancer. This review describes healthcare disparities in the changing landscape of non-small cell lung cancer (NSCLC) in the United States, focusing on racial, ethnic, sex-based, and socioeconomic trends. Furthermore, strategies to address disparities, overcome challenges, and improve patient outcomes are proposed. Barriers exist across lung cancer screening, diagnosis, and treatment regimens, varying by sex, age, race and ethnicity, geography, and socioeconomic status. Incidence and mortality rates of lung cancer are higher among Black men than White men, and incidences in young women are substantially greater than in young men. Disparities may be attributed to geographic differences in screening access, with correlating higher incidence and mortality rates in rural versus urban areas. Lower socioeconomic status is also linked to lower survival rates. Several strategies could help reduce disparities and improve outcomes. Current guidelines could improve screening eligibility by incorporating sex, race, and socioeconomic status variables. Patient and clinician education on screening guidelines and patient-level barriers to care are key, and biomarker testing is critical since ~ 70% of patients with NSCLC have an actionable biomarker. Timely diagnosis, staging, and comprehensive biomarker testing, including cell-free DNA liquid biopsy, may provide valuable treatment guidance for patients with NSCLC. Efforts to improve lung cancer screening and biomarker testing access, decrease bias, and improve education about screening and testing are needed to reduce healthcare disparities in NSCLC.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1217-1231"},"PeriodicalIF":4.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140944098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mechanical deformation and death of circulating tumor cells in the bloodstream. 血液中循环肿瘤细胞的机械变形和死亡。

IF 7.7 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-07-09 DOI: 10.1007/s10555-024-10198-3

Yunxiu Qiu, Tong Gao, Bryan Ronain Smith

{"title":"Mechanical deformation and death of circulating tumor cells in the bloodstream.","authors":"Yunxiu Qiu, Tong Gao, Bryan Ronain Smith","doi":"10.1007/s10555-024-10198-3","DOIUrl":"10.1007/s10555-024-10198-3","url":null,"abstract":"The circulation of tumor cells through the bloodstream is a significant step in tumor metastasis. To better understand the metastatic process, circulating tumor cell (CTC) survival in the circulation must be explored. While immune interactions with CTCs in recent decades have been examined, research has yet to sufficiently explain some CTC behaviors in blood flow. Studies related to CTC mechanical responses in the bloodstream have recently been conducted to further study conditions under which CTCs might die. While experimental methods can assess the mechanical properties and death of CTCs, increasingly sophisticated computational models are being built to simulate the blood flow and CTC mechanical deformation under fluid shear stresses (FSS) in the bloodstream.Several factors contribute to the mechanical deformation and death of CTCs as they circulate. While FSS can damage CTC structure, diverse interactions between CTCs and blood components may either promote or hinder the next metastatic step-extravasation at a remote site. Overall understanding of how these factors influence the deformation and death of CTCs could serve as a basis for future experiments and simulations, enabling researchers to predict CTC death more accurately. Ultimately, these efforts can lead to improved metastasis-specific therapeutics and diagnostics specific in the future.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1489-1510"},"PeriodicalIF":7.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in the molecular biology of the solitary fibrous tumor and potential impact on clinical applications. 单发纤维瘤分子生物学研究进展及对临床应用的潜在影响。

IF 4.4 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-08-09 DOI: 10.1007/s10555-024-10204-8

Chongmin Ren, Gina D'Amato, Francis J Hornicek, Hao Tao, Zhenfeng Duan

{"title":"Advances in the molecular biology of the solitary fibrous tumor and potential impact on clinical applications.","authors":"Chongmin Ren, Gina D'Amato, Francis J Hornicek, Hao Tao, Zhenfeng Duan","doi":"10.1007/s10555-024-10204-8","DOIUrl":"10.1007/s10555-024-10204-8","url":null,"abstract":"Solitary fibrous tumor (SFT) is a rare fibroblastic mesenchymal neoplasm. The current classification has merged SFT and hemangiopericytoma (HPC) into the same tumor entity, while the risk stratification models have been developed to compensate for clinical prediction. Typically, slow-growing and asymptomatic, SFT can occur in various anatomical sites, most commonly in the pleura. Histologically, SFT consists of spindle to oval cells with minimal patterned growth, surrounded by stromal collagen and unique vascular patterns. Molecularly, SFT is defined by the fusion of NGFI-A-binding protein 2 (NAB2) and signal transducer and activator of transcription 6 (STAT6) genes as NAB2-STAT6. This fusion transforms NAB2 into a transcriptional activator, activating early growth response 1 (EGR1) and contributing to SFT pathogenesis and development. There are several fusion variants of NAB2-STAT6 in tumor tissues, with the most frequent ones being NAB2ex4-STAT6ex2 and NAB2ex6-STAT6ex16/ex17. Diagnostic methods play a crucial role in SFT clinical practice and basic research, including RT-PCR, next-generation sequencing (NGS), FISH, immunohistochemistry (IHC), and Western blot analysis, each with distinct capabilities and limitations. Traditional treatment strategies of SFT encompass surgical resection, radiation therapy, and chemotherapy, while emerging management regimes include antiangiogenic agents, immunotherapy, RNA-targeting technologies, and potential targeted drugs. This review provides an update on SFT's clinical and molecular aspects, diagnostic methods, and potential therapies.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1337-1352"},"PeriodicalIF":4.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554739/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tumor necrosis factor superfamily signaling: life and death in cancer. 肿瘤坏死因子超家族信号传导：癌症中的生与死。

IF 4.4 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-10-04 DOI: 10.1007/s10555-024-10206-6

Obada Ababneh, Daisuke Nishizaki, Shumei Kato, Razelle Kurzrock

{"title":"Tumor necrosis factor superfamily signaling: life and death in cancer.","authors":"Obada Ababneh, Daisuke Nishizaki, Shumei Kato, Razelle Kurzrock","doi":"10.1007/s10555-024-10206-6","DOIUrl":"10.1007/s10555-024-10206-6","url":null,"abstract":"Immune checkpoint inhibitors have shaped the landscape of cancer treatment. However, many patients either do not respond or suffer from later progression. Numerous proteins can control immune system activity, including multiple tumor necrosis factor (TNF) superfamily (TNFSF) and TNF receptor superfamily (TNFRSF) members; these proteins play a complex role in regulating cell survival and death, cellular differentiation, and immune system activity. Notably, TNFSF/TNFRSF molecules may display either pro-tumoral or anti-tumoral activity, or even both, depending on tumor type. Therefore, TNF is a prototype of an enigmatic two-faced mediator in oncogenesis. To date, multiple anti-TNF agents have been approved and/or included in guidelines for treating autoimmune disorders and immune-related toxicities after immune checkpoint blockade for cancer. A confirmed role for the TNFSF/TNFRSF members in treating cancer has proven more elusive. In this review, we highlight the cancer-relevant TNFSF/TNFRSF family members, focusing on the death domain-containing and co-stimulation members and their signaling pathways, as well as their complicated role in the life and death of cancer cells.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1137-1163"},"PeriodicalIF":4.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554763/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multifaceted role of the DNA replication protein MCM10 in maintaining genome stability and its implication in human diseases. DNA 复制蛋白 MCM10 在维持基因组稳定性中的多方面作用及其对人类疾病的影响。

IF 7.7 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-09-06 DOI: 10.1007/s10555-024-10209-3

Sumayyah M Q Ahmed, Jayaprakash Sasikumar, Suparna Laha, Shankar Prasad Das

{"title":"Multifaceted role of the DNA replication protein MCM10 in maintaining genome stability and its implication in human diseases.","authors":"Sumayyah M Q Ahmed, Jayaprakash Sasikumar, Suparna Laha, Shankar Prasad Das","doi":"10.1007/s10555-024-10209-3","DOIUrl":"10.1007/s10555-024-10209-3","url":null,"abstract":"MCM10 plays a vital role in genome duplication and is crucial for DNA replication initiation, elongation, and termination. It coordinates several proteins to assemble at the fork, form a functional replisome, trigger origin unwinding, and stabilize the replication bubble. MCM10 overexpression is associated with increased aggressiveness in breast, cervical, and several other cancers. Disruption of MCM10 leads to altered replication timing associated with initiation site gains and losses accompanied by genome instability. Knockdown of MCM10 affects the proliferation and migration of cancer cells, manifested by DNA damage and replication fork arrest, and has recently been shown to be associated with clinical conditions like CNKD and RCM. Loss of MCM10 function is associated with impaired telomerase activity, leading to the accumulation of abnormal replication forks and compromised telomere length. MCM10 interacts with histones, aids in nucleosome assembly, binds BRCA2 to maintain genome integrity during DNA damage, prevents lesion skipping, and inhibits PRIMPOL-mediated repriming. It also interacts with the fork reversal enzyme SMARCAL1 and inhibits fork regression. Additionally, MCM10 undergoes several post-translational modifications and contributes to transcriptional silencing by interacting with the SIR proteins. This review explores the mechanism associated with MCM10's multifaceted role in DNA replication initiation, chromatin organization, transcriptional silencing, replication stress, fork stability, telomere length maintenance, and DNA damage response. Finally, we discuss the role of MCM10 in the early detection of cancer, its prognostic significance, and its potential use in therapeutics for cancer treatment.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1353-1371"},"PeriodicalIF":7.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Racial disparity in prostate cancer: an outlook in genetic and molecular landscape. 前列腺癌的种族差异：基因和分子状况展望。

IF 7.7 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-06-20 DOI: 10.1007/s10555-024-10193-8

Jyoti B Kaushal, Pratima Raut, Sakthivel Muniyan, Jawed A Siddiqui, Zahraa W Alsafwani, Parthasarathy Seshacharyulu, Sujit S Nair, Ashutosh K Tewari, Surinder K Batra

{"title":"Racial disparity in prostate cancer: an outlook in genetic and molecular landscape.","authors":"Jyoti B Kaushal, Pratima Raut, Sakthivel Muniyan, Jawed A Siddiqui, Zahraa W Alsafwani, Parthasarathy Seshacharyulu, Sujit S Nair, Ashutosh K Tewari, Surinder K Batra","doi":"10.1007/s10555-024-10193-8","DOIUrl":"10.1007/s10555-024-10193-8","url":null,"abstract":"Prostate cancer (PCa) incidence, morbidity, and mortality rates are significantly impacted by racial disparities. Despite innovative therapeutic approaches and advancements in prevention, men of African American (AA) ancestry are at a higher risk of developing PCa and have a more aggressive and metastatic form of the disease at the time of initial PCa diagnosis than other races. Research on PCa has underlined the biological and molecular basis of racial disparity and emphasized the genetic aspect as the fundamental component of racial inequality. Furthermore, the lower enrollment rate, limited access to national-level cancer facilities, and deferred treatment of AA men and other minorities are hurdles in improving the outcomes of PCa patients. This review provides the most up-to-date information on various biological and molecular contributing factors, such as the single nucleotide polymorphisms (SNPs), mutational spectrum, altered chromosomal loci, differential gene expression, transcriptome analysis, epigenetic factors, tumor microenvironment (TME), and immune modulation of PCa racial disparities. This review also highlights future research avenues to explore the underlying biological factors contributing to PCa disparities, particularly in men of African ancestry.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1233-1255"},"PeriodicalIF":7.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141431487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Classification of anticancer drugs: an update with FDA- and EMA-approved drugs. 抗癌药物分类：美国 FDA 和 EMA 批准药物的更新。

IF 7.7 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-07-05 DOI: 10.1007/s10555-024-10188-5

Lorena Ostios-Garcia, Daniel Martínez Pérez, Beatriz Castelo, Noelia Hernández Herradón, Pilar Zamora, Jaime Feliu, Enrique Espinosa

引用次数: 0

Failure to progress: breast and prostate cancer cell lines in developing targeted therapies. 进展失败：开发靶向疗法的乳腺癌和前列腺癌细胞系。

IF 7.7 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-07-26 DOI: 10.1007/s10555-024-10202-w

Chelsi James, Akeem Whitehead, Jasmine T Plummer, Rory Thompson, Simone Badal

{"title":"Failure to progress: breast and prostate cancer cell lines in developing targeted therapies.","authors":"Chelsi James, Akeem Whitehead, Jasmine T Plummer, Rory Thompson, Simone Badal","doi":"10.1007/s10555-024-10202-w","DOIUrl":"10.1007/s10555-024-10202-w","url":null,"abstract":"Developing anticancer drugs from preclinical to clinical takes approximately a decade in a cutting-edge biomedical lab and still 97% of most fail at clinical trials. Cell line usage is critical in expediting the advancement of anticancer therapies. Yet developing appropriate cell lines has been challenging and overcoming these obstacles whilst implementing a systematic approach of utilizing 3D models that recapitulate the tumour microenvironment is prudent. Using a robust and continuous supply of cell lines representing all ethnic groups from all locales is necessary to capture the evolving tumour landscape in culture. Next, the conversion of these models to systems on a chip that can by way of high throughput cytotoxic assays identify drug leads for clinical trials should fast-track drug development while markedly improving success rates. In this review, we describe the challenges that have hindered the progression of cell line models over seven decades and methods to overcome this. We outline the gaps in breast and prostate cancer cell line pathology and racial representation alongside their involvement in relevant drug development.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1529-1548"},"PeriodicalIF":7.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141765550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Functional and clinical roles of stromal PDGF receptors in tumor biology. 基质 PDGF 受体在肿瘤生物学中的功能和临床作用。

IF 4.4 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-07-09 DOI: 10.1007/s10555-024-10194-7

Carina Strell, Elisabet Rodríguez-Tomàs, Arne Östman

{"title":"Functional and clinical roles of stromal PDGF receptors in tumor biology.","authors":"Carina Strell, Elisabet Rodríguez-Tomàs, Arne Östman","doi":"10.1007/s10555-024-10194-7","DOIUrl":"10.1007/s10555-024-10194-7","url":null,"abstract":"PDGF receptors play pivotal roles in both developmental and physiological processes through the regulation of mesenchymal cells involved in paracrine instructive interactions with epithelial or endothelial cells. Tumor biology studies, alongside analyses of patient tissue samples, provide strong indications that the PDGF signaling pathways are also critical in various types of human cancer. This review summarizes experimental findings and correlative studies, which have explored the biological mechanisms and clinical relevance of PDGFRs in mesenchymal cells of the tumor microenvironment. Collectively, these studies support the overall concept that the PDGF system is a critical regulator of tumor growth, metastasis, and drug efficacy, suggesting yet unexploited targeting opportunities. The inter-patient variability in stromal PDGFR expression, as being linked to prognosis and treatment responses, not only indicates the need for stratified approaches in upcoming therapeutic investigations but also implies the potential for the development of PDGFRs as biomarkers of clinical utility, interestingly also in settings outside PDGFR-directed treatments.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1593-1609"},"PeriodicalIF":4.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0